Merck Stock Outshines Nasdaq Amid Cancer Treatment Breakthrough

Merck & Co., Inc. (MRK), a global biopharmaceutical company, is outperforming the Nasdaq Composite index over various time frames. The company's pharmaceutical portfolio spans oncology, vaccines, cardiometabolic disease, and infectious diseases, among others.

The stock has slipped 5.5% from its 52-week high of $156.92 reached on August 25 but is up 23.7% over the past three months, outperforming the Nasdaq's 1.9% fall during the same time frame.

Over the past year, MRK has surged 78.3%, while the Nasdaq delivered 21.6% returns. In 2026, the stock is up 40.9%, surpassing the index's 13.6% growth.

The company's recent breakthrough in cancer treatment has contributed to its success. On August 19, Merck shares jumped 11.3% after the company and partner Moderna announced a Phase 3 win for their personalized mRNA cancer vaccine, intismeran autogene, in combination with Keytruda.

The regimen significantly reduced the risk of melanoma recurrence or death and improved distant metastasis-free survival versus Keytruda alone. Wall Street is taking a moderately optimistic stance on MRK, with an overall consensus rating of 'Moderate Buy' among 28 analysts covering the stock.